Table 1 Characteristics of included studies
Study characteristics | Outcome definitions | ||||
|---|---|---|---|---|---|
First author[year] | Country | Design | Remission criteria(clinical remission or CS-free clinical remission) | Response criteria | Mucosal healing criteria |
Singh[2016] [22] | USA | Retrospective case series | Clinical remission: PUCAI < 10 or wPCDAI < 12.5 | NR | NR |
Conrad[2016] [23] | USA | Prospective case series | Steroid-free remission: Inactive disease by PCDAI (≤ 10) or PUCAI (< 10) and no current corticosteroid therapy | PCDAI decrease ≥ 12.5;PUCAI decrease ≥ 20; | NR |
Ledder[2017] [24] | Multi-country | Retrospective case series | Steroid-and exclusive enteral nutrition [EEN]-free remission: wPCDAI < 12.5 or PUCAI < 10 without the need for new medications or surgical intervention; | NR | SES-CD < 3 in CD or UCEIS = 0 in UC/IBD-U |
Schneider[2018] [25] | Austria | Retrospective case series | Clinical remission: shPCDAI < 10 points; PUCAI < 10 points | NR | NR |
Olbjørn[2020] [26] | Norway | Case series | NR | NR | NR |
Jossen[2020] [27] | USA | Retrospective case series | CS-free clinical remission: PCDAI < 12.5, or partial Mayo score < 2 and off corticosteroids | NR | Endoscopic remission and Histologic remission: Endoscopic remission: Mayo Score = 0;SES-CD score ≤ 2; Histological remission: Nancy Index score ≤ 1 in UC and a CD histologic activity score ≤ 1 in every segment; |
Dolinger[2021] [28] | USA | Prospective case series | CS-free remission: wPCDAI ≤ 12.5 or pMS < 2, and no form of corticosteroids for at least 4 weeks | NR | NR |
Fabiszewska[2021] [29] | Poland | Retrospective case series | Clinical remission: PCDAI ≤ 10 or PUCAI ≤ 10 after induction phase (4th dose week) and maintenance phase (10th dose week) | PCDAI decrease ≥ 12.5;PUCAI decrease ≥ 20 after 4th dose week | The level of FCP: a statistically significant decrease in FCP level between baseline and after vedolizumab commencement |
Garcia-Romero [2021] [30] | Span | Retrospective case series | Clinical remission: PCDAI < 10 or PUCAI < 10 | PCDAI decrease ≥ 15 and final PCDAI < 30;. PUCAI decrease ≥ 20 | NR |
Hajjat[2021] [31] | USA | Retrospective case series | CS-free clinical remission: PCDAI ≤ 10;PUCAI < 10 | NR | NR |